Matt Whiteman
Inventor, Co-founder and CSO at MitoRx Therapeutics and professor at Mahidol University in Thailand
Professor of Experimental Therapeutics, University of Exeter, University of Otago, NZ (2006) and University of Mahidol, Thailand (2018, 2022-). Key to elucidating the role of H₂S in vivo and invented the first mitochondrial-targeted sulfide-delivery molecules. Grant awards totalling £6m for mitochondrial H₂S rescue of diseases. 20 years experience of redox biochemistry and pharmacology in UK and Singapore. 180+ publications, H-index = 78.
Visit website: https://www.mitorxtherapeutics.com/#Our-team/#matt
See also: MitoRx Therapeutics - Pre-clinical stage rare disease biotech company aiming to develop treatments for degenerative diseases
Details last updated 27-Aug-2022
Matt Whiteman is also referenced in the following:
MitoRx Therapeutics
Pre-clinical stage rare disease biotech company aiming to develop treatments for degenerative diseases
Matt Whiteman News
Penetrable sunscreen agents could reverse skin damage and ageing
SciTechDaily - 12-Aug-2021
Two novel compounds fuel mitochondria to maintain energy balance and lower UV damage in the skin
Read more...